Detailed price information for Vigil Neuroscience Inc (VIGL-Q) from The Globe and Mail including charting and trades.

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’ s disease to the neurology pipeline. Paris, May 22, 2025. Sanofi announced today that it has ...

--Vigil Neuroscience, Inc., a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases and Sanofi, today announced that ...

- Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following ...

Today’s chaos. Tomorrow’s opportunity. Join for Free » Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP Jun. 04, 2025 7:00 AM ET Vigil Neuroscience, Inc. (VIGL) ...

Fintel reports that on May 28, 2025, Stifel downgraded their outlook for Vigil Neuroscience (NasdaqGS:VIGL) from Buy to Hold. Analyst Price Forecast Suggests 99.71% Upside As of May 7, 2025, the ...

Net Loss: Net loss from operations for the first quarter ended March 31, 2025 were $22.4 million, compared to $19.9 million for the same period in 2024. About Vigil Neuroscience ...

WATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment ...

Vigil Neuroscience shares more than tripled in premarket trading a day after Sanofi agreed to acquire Vigil for about $470 million. Vigil shares were trading around $8. The stock was up 36% on the ...

Vigil Neuroscience, Inc. (VIGL) closed the last trading session at $7.88, gaining 225.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vigil Neuroscience, a new biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, launched today with $50 ...